


# The CF World has been turning to Creon for years



**creon**<sup>®</sup>  
pancreatin



Because CF patients need all the help they can get

#### PRESCRIBING INFORMATION

**Presentation** 1. Creon - brown/yellow capsules containing enteric coated granules of pancreatin, equivalent to: 8,000 PhEur units of lipase; 9,000 PhEur units of amylase and 450 PhEur units (total) of protease (210 BP units). Available in packs of 100. Basic NHS price of £13.33. PL 5727/0001. 2. Creon sachets - unit dose sachets containing enteric coated granules of pancreatin, equivalent to: 20,000 PhEur units of lipase, 22,500 PhEur units of amylase and 1,125 PhEur units (total) of protease. Available in packs of 40. Basic NHS price of £13.33. PL 5727/0007.

**Indication** Pancreatic exocrine insufficiency.

**Dosage and Administration:** Adults and children: 1. Creon - initially one or two capsules with meals, then adjust according to response. 2. Creon sachets - initially the contents of one sachet with meals, then adjust according to response. (Note that two sachets of Creon granules are equivalent to five capsules of Creon.) The contents of each sachet can be taken from a spoon or tipped directly onto the tongue, and then washed down with a drink of water or other fluid. The granules contained in Creon capsules or sachets can also be sprinkled on soft food, which should then be

swallowed without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

**Contra-indications, Warnings etc.** **Contra-indications:** substitution with pancreatic enzymes is contra-indicated in the early states of acute pancreatitis. Use in pregnancy: there is inadequate evidence of safety in use during pregnancy. **Warnings:** The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with very high doses of pancreatin. Perianal irritation, and rarely, inflammation, could occur when large doses are used.

**Legal Classification:** P

**Name and Address of Licence Holder:** Kali Chemie Pharma GmbH, Postfach 220, D-30173, Hannover 1, Germany.

**Further information available from:** Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO18 3JD. Tel: 0703 472281.

Date of preparation August 1994

© Registered Trade Mark CRE/CF/JA/8/94



**DUPHAR  
LABORATORIES**

## THIRD EDITION




By  
**JOHN FEELY**

This fully revised third edition of *New Drugs* will help doctors to keep up to date with the latest developments in new and existing drugs. This invaluable guide:

- Describes all drugs in common use
- Covers all of the important therapeutic advances
- Deals with specific diseases and the drugs used
- Describes adverse reactions
- Considers treatment of special groups, including infants and children

"A valuable review for any prescriber." *Palliative Medicine*  
"Recommended as a good buy." *Postgraduate Medical Journal*

UK £17.95; Overseas £20.00 (BMA members £16.95; £19.00)  
ISBN: 07279 0821 9 464 pages 1994



### ORDER FORM

British Medical Journal, PO Box 295, London WC1H 9TE  
Please send me the following books:

Qty	Title	Amount

Prices include postage by air abroad Total £

Please send me a BMJ Publishing Group catalogue

Name \_\_\_\_\_

Address \_\_\_\_\_

Postcode \_\_\_\_\_

Cheque enclosed (made payable to British Medical Journal) £ \_\_\_\_\_

Membership No. \_\_\_\_\_

Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No. \_\_\_\_\_ Expiry date \_\_\_\_\_

Signature \_\_\_\_\_

BMJ books are also available at major booksellers  
or the BMJ bookshop at BMA House.

### Epilim Oral Prescribing Information

**Presentation** Epilim 200 Enteric Coated and Epilim 500 Enteric Coated: Enteric coated tablets containing 200mg, and 500mg Sodium Valproate Ph.Eur. respectively. Epilim Crushable Tablets containing 100mg Sodium Valproate Ph.Eur. Epilim Syrup and Epilim Liquid (sugar free) both containing 200mg Sodium Valproate Ph.Eur. per 5ml. Epilim Chrono 200, Epilim Chrono 300, and Epilim Chrono 500: Controlled release tablets containing a mixture of Sodium Valproate Ph.Eur. and Valproic Acid Fr.P. equivalent to 200mg, 300mg, and 500mg Sodium Valproate respectively.

**Indications** Oral formulations of Epilim are indicated for all types of epilepsy. In women of child bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and administration** *Adults*; the dose should be titrated at three day intervals until seizure control is achieved. Initially 600mg a day in divided doses increasing in steps of 200mg to a maximum dose of 2500mg per day. *Children over 20kg*; initially 400mg a day in divided doses increasing in steps to a maximum dose of 35mg/kg/day. *Children under 20kg*; initially 20mg/kg/day - the dose may be increased in steps to a maximum of 40mg/kg/day provided that plasma levels are monitored. Epilim Chrono 500 may be given once or twice daily. All other formulations should be given twice daily. **Combination therapy**; levels of Epilim and co-administered anticonvulsants may be affected and optimum dosage is determined by seizure control. **Contraindications, Warnings, etc.** **Contraindications** Active liver disease, family history of severe liver disease, hypersensitivity to valproate. **Side effects** Impaired hepatic function, particularly in children, occasionally leading to hepatic failure - treatment should be withdrawn in patients who suddenly develop symptoms compatible with hepatic disease such as nausea, anorexia, jaundice or malaise. **Hyperammonaemia** with or without hepatic dysfunction. Blood dyscrasia - impaired platelet function, thrombocytopenia, occasional leucopenia and red cell hypoplasia. Occasionally increased appetite, weight gain, transient hair loss, behavioural disturbances, alterations to the menstrual cycle and pancreatitis. Symptoms of intoxication include ataxia, tremor, and stupor. **Drug interactions** Epilim has significant interactions with phenytoin, lamotrigine and other anticonvulsants. Epilim may potentiate the effects of neuroleptics, MAOIs and other antidepressants, anticoagulants and salicylates. Cimetidine may inhibit the metabolism of Epilim. Epilim has no effect on the efficacy of oral contraceptives. **Pregnancy** An increased incidence of congenital abnormalities has been demonstrated in offspring born to mothers with epilepsy both untreated and treated, including those treated with sodium valproate. Neural tube defects have been reported in about 1% of offspring of women who have received valproate during the first trimester of pregnancy. Pregnancies should be screened for neural tube defects by estimation of alpha-fetoprotein and ultrasound. Folate supplementation has been shown to reduce the incidence of neural tube defects in the offspring of high risk women. **Legal category** P.O.M. **Further information** Epilim is hygroscopic - tablets should not be removed from their foil until they are used. Epilim Chrono is recommended in cases where plasma valproate levels are being measured on account of its pharmacokinetics. The effective therapeutic range for valproate is 40-100mg/l (278-694 micromol/l). **Product Licence Numbers** Epilim 200 Enteric Coated 11723/0018, Epilim 500 Enteric Coated 11723/0020, Epilim 100mg Crushable Tablets 11723/0017, Epilim Syrup 11723/0025, Epilim Liquid 11723/0024, Epilim Chrono 200 11723/0078, Epilim Chrono 300 11723/0021, Epilim Chrono 500 11723/0079. **NHS Cost** Epilim 200 Enteric Coated 100 tablets £6.42, Epilim 500 Enteric Coated 100 tablets £16.04, Epilim 100mg Crushable Tablets 100 tablets £3.89, Epilim Syrup 300ml £5.89, Epilim Liquid 300ml £5.89, Epilim Chrono 200 100 tablets £7.70, Epilim Chrono 300 100 tablets £11.55, Epilim Chrono 500 100 tablets £19.25. **Address:** Sanofi Winthrop Ltd., One Onslow Street, Guildford, Surrey GU1 4YS. **Telephone:** (01483) 505515 **Fax:** (01483) 35432. Epilim, Epilim Chrono and the Chrono device are registered trade marks. **Date of preparation** April 1995.

### References:

1. Chadwick D., *J. Neurol. Neurosurg. Psychiatry* 1994; 57: 264-277.
2. Gilham R.A., *Epilepsy Res.*, 1990; 7: 219-225.



# Give someone with epilepsy a future to look forward to

People with epilepsy have the same aspirations as anybody else. What they need is a treatment which allows them to fulfil their potential.

Whatever the type of epilepsy, Epilim Chrono can help. Effective both in generalized and partial seizures,<sup>1</sup> it is well tolerated (particularly with regard to cognitive function)<sup>2</sup>, and offers patients the convenience of once-daily dosing.\*

It helps people with epilepsy get on with their lives today, and look forward to tomorrow.




\*500mg Tablets  
**Epilim<sup>®</sup> CHRONO<sup>®</sup>**  
Sodium Valproate Ph. Eur.  
Valproic Acid Fr.P.   
Controlled Release

Once-daily management  
for all forms of epilepsy

**ABBREVIATED PRESCRIBING INFORMATION:**

Presentation UNIPHILLIN CONTINUS tablets contain Theophylline BP in a controlled release system. UNIPHILLIN CONTINUS tablets 400 mg are white, capsule-shaped, scored tablets with the logo NAPP U400 embossed on one side and UNIPHILLIN on the other. UNIPHILLIN CONTINUS tablets 300 mg are white, capsule-shaped, scored tablets with U300 embossed on one side. UNIPHILLIN CONTINUS tablets 200 mg are white, capsule-shaped, scored tablets with U200 embossed on one side. Uses Theophylline is a bronchodilator. In addition it affects the function of a number of cells involved in the inflammatory processes associated with asthma and chronic obstructive airways disease. Of most importance may be enhanced suppressor T-lymphocyte activity and reduction of eosinophil and neutrophil function. These actions may contribute to anti-inflammatory prophylactic activity in asthma and chronic obstructive airways disease. For the treatment and prophylaxis of bronchospasm associated with asthma, emphysema and chronic bronchitis. Also indicated in adults for the treatment of cardiac asthma and left ventricular or congestive cardiac failure. Dosage and administration NB Tablets should be swallowed whole and not chewed. Adults: The usual maintenance dose for elderly patients or those less than 70 kg body weight is 300 mg, 12-hourly following an initial week of therapy on 200 mg, 12-hourly. The usual maintenance dose for patients of 70 kg body weight or over is 400 mg, 12-hourly following an initial week of therapy on 200 mg or 300 mg, 12-hourly. Children: Not recommended for children under seven years of age. The maintenance dose is 9 mg/kg twice daily. Some children with chronic asthma require and tolerate much higher doses (10-16 mg/kg twice daily). Lower dosages (based on usual adult dose) may be required by adolescents. It may be appropriate to administer a larger evening or morning dose in some patients, in order to achieve optimum therapeutic effect when symptoms are quite severe, e.g. at the time of the 'morning dip' in lung function. In patients whose night time or day time symptoms persist despite other therapy and who are not currently receiving theophylline, then the total daily requirement of UNIPHILLIN CONTINUS tablets (as specified above) may be added to their treatment regimen as either a single evening or morning dose. Elderly: The initial dose should be 200 mg, 12-hourly increasing to 300 mg, 12-hourly. Contra-indications Should not be given concomitantly with ephedrine in children. Precautions and warnings The following increase clearance and it may therefore be necessary to increase dosage to ensure a therapeutic effect: phenytoin, carbamazepine, rifampicin, sulphapyrazone and barbiturates. Smoking and alcohol consumption can also increase clearance of theophylline. The following reduce clearance and a reduced dosage may therefore be necessary to avoid side-effects: allopurinol, cimetidine, ciprofloxacin, erythromycin, thiazolidazole, isoprenaline, fluvoxamine, viloxazine hydrochloride and oral contraceptives. Factors such as viral infections, liver disease and heart failure also reduce theophylline clearance. The hypokalaemia resulting from beta<sub>2</sub> agonists, corticosteroids, diuretics

significantly reduced when UNIPHILLIN CONTINUS tablet preparations are given. Furthermore, the side effects can be minimised by dose titration downwards. Transferability It is not possible to ensure bioequivalence between different sustained release theophylline products. Therefore, it should be emphasised that patients, once titrated to an effective dose, should not be changed from UNIPHILLIN CONTINUS tablet preparations to other slow or sustained release xanthine preparations without re-titration and clinical assessment. Legal category P. Package quantities and basic NHS price UNIPHILLIN CONTINUS tablets 400 mg - 56's: £7.32; 250's: £32.36; 1,000's: £125.29. UNIPHILLIN CONTINUS tablets 300 mg - 56's: £6.17; 250's: £27.89. UNIPHILLIN CONTINUS tablets 200 mg - 56's: £4.05. Product licence numbers UNIPHILLIN CONTINUS tablets 400 mg - PL 0337/0074. UNIPHILLIN CONTINUS tablets 300 mg - PL 0337/0129. UNIPHILLIN CONTINUS tablets 200 mg - PL 0337/0057. Product licence holder Napp Laboratories Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4GW, UK. Tel: 01223 424444. Member of Napp Pharmaceutical Group. Further information is available from Napp Laboratories Limited. © The NAPP device, UNIPHILLIN and CONTINUS are Registered Trade Marks. © NAPP Laboratories Limited 1995. Reference: I. Kidney J, Dominguez M, Taylor PM, et al. (In press). Date of preparation: April 1995.



There's a new  
dimension to  
UNIPHILLIN

For over 50 years, theophylline has been regarded as a bronchodilator. New evidence<sup>1</sup> demonstrates that this is only part of the story.

UNIPHILLIN CONTINUS tablets are now believed to exert an anti-inflammatory action. They therefore present a convenient and acceptable choice for preventive therapy - and add a new dimension to asthma management.

DUAL ACTION

**Uniphyllin**<sup>®</sup>

CONTINUS • TABLETS THEOPHYLLINE BP

**Breathing new life into asthma therapy**

**ABBREVIATED PRESCRIBING INFORMATION FOR DIFLUCAN\***

**(fluconazole) (UK) Presentation:** Capsules containing 50mg, 150mg or 200mg fluconazole; intravenous infusion containing fluconazole 2mg/ml in 0.9% sodium chloride solution; Powder for Oral Suspension available as two dosage strengths containing either fluconazole 50mg/5ml or 200mg/5ml on reconstitution with 24ml water. **Indications and dosage:** **Adults:** Systemic candidiasis: 400mg on the first day followed by 200-400mg once daily. Cryptococcosis, including meningitis: 400mg on the first day followed by 200-400mg once daily. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS: 100-200mg daily. Oropharyngeal candidiasis: 50-100mg once daily for 7-14 days or longer in immunocompromised patients. Other mucosal candidal infections: 50-100mg once daily for 14-30 days. Prevention of fungal infections in neutropenic patients following cytotoxic chemotherapy or radiotherapy: 50-400mg once daily based on patient's risk for developing fungal infection. For patients at high risk of systemic infection, eg patients who are anticipated to have profound or prolonged neutropenia such as during bone marrow transplantation, the recommended dose is 400mg daily. Start dosage several days before anticipated onset of neutropenia and continue for seven days after neutrophil count rises above 1000 cells per mm<sup>3</sup>. Dermal fungal infections: 50mg once daily for up to 6 weeks (usually 2-4 weeks - see data sheet). Vaginal candidiasis: Single 150mg dose. Use in the elderly - as above except for those renally impaired - see data sheet. **Children: Over 4 weeks old:** Mucosal candidiasis: 3mg/kg daily. A loading dose of 6mg/kg may be used on the first day. Systemic candidiasis and cryptococcal infection: 6-12mg/kg daily depending on severity of disease. Prevention of fungal infections in neutropenic patients following cytotoxic chemotherapy or radiotherapy: 3-12mg/kg daily depending on the extent and duration of the neutropenia. **Children below 4 weeks of age:** First two weeks of life: The same mg/kg dosing as above but administered every 72 hours. During weeks 2-4 of life same mg/kg dose should be given every 48 hours. Doses of less than 10mg fluconazole should only be administered in hospital. A suitable measuring device should be used for administration of the suspension. **Administration:** DIFLUCAN may be administered either orally or by intravenous infusion at a rate of approximately 5-10ml/min. The dosages for the two routes are equivalent. **Contra-indications:** Hypersensitivity to fluconazole or related azoles, pregnancy and women of childbearing potential unless adequate contraception is employed. **Warnings:** Lactation: Not recommended. Renal impairment: Dosage reduction in both adults and children may be necessary, see data sheet. **Drug interactions:** Anticoagulants, cyclosporin, oral sulphonylureas, phenytoin, rifampicin and theophylline. **Side-effects:** Nausea, abdominal discomfort, diarrhoea, flatulence and rarely anaphylaxis. **Legal Category:** POM. **Basic NHS Cost and Package Quantities:** DIFLUCAN capsules in calendar packs containing 7x50mg (£16.61, PL 57/0289), 7x200mg (£66.42, PL 57/0317) or 1x150mg (£7.12, PL 57/0290); Powder for Oral Suspension, 35ml bottle of 50mg/5ml (£16.61, PL 57/0343), 35ml bottle of 200mg/5ml (£66.42, PL 57/0344); Intravenous Infusion: 25ml (50mg) bottle (£7.32, PL 57/0315); 100ml (200mg) bottle (£29.28, PL 57/0315). Hospital prices are available on request. † DIFLUCAN is well tolerated with few adverse effects: Marchisio P *et al.* (1994) *Eur J Clin Microbiol Infect Dis* 13: 338-340. Fasano C *et al.* (1994) *Eur J Clin Microbiol Infect Dis* 13: 344-347. Further information on request. \* Trade Mark. Pfizer Limited, Sandwich, Kent. 51336 March 1995.



**HITS CHILDREN'S  
FUNGAL INFECTIONS  
HARD...**

**...WITH BARELY  
A RIPPLE†**

**Diflucan\***  
fluconazole

**GENTLE STRENGTH**



An der Universität Bern (Medizinische Fakultät), ist die Stelle der/des


## Direktorin/Direktor der Medizinischen Kinderklinik

im Range einer(s) Ordinaria/Ordinarius auf den 1. April 1996 neu zu besetzen.

Habilitierte Bewerber(innen) mit ausgewiesener Lehrbefähigung, mit allgemeiner Anerkennung als Forscher, mit weiter pädiatrischer Fachkompetenz, gestützt auf wissenschaftliche Spezialisierung und solide klinische Erfahrung, sollen erfahren und befähigt in der Ausübung von Führungsaufgaben sein, Offenheit und interdisziplinäre Kooperationsbereitschaft zeigen und zur aktiven Mitarbeit am nationalen pädiatrischen Schwerpunktprogramm und an der Realisierung neuer Führungs- und Administrationsmodelle bereit sein.

Sie werden gebeten, ihren Lebenslauf mit Literaturverzeichnis und 5 Sonderdrucken (je 3 Kopien) der wichtigsten Arbeiten sowie Angaben über ihre bisherige Tätigkeit bis zum 31. Juli 1995 an die Erziehungsdirektion des Kantons Bern, Amt für Hochschulen, Abt. Universität (1300.33/94), Sulgeneckstrasse 70, CH-3005 Bern, einzureichen.

Für Auskünfte steht der Präsident der vorbereitenden Kommission, Prof. R. Greiner, Klinik für Radio-Onkologie, Inselspital, CH-3010 Bern, Tel 031 632 24 10, Fax 031 382 23 42, zur Verfügung.



## SYSTEMATIC REVIEWS

Edited by Iain Chalmers, UK  
Cochrane Centre NHS Research and  
Development Programme, Oxford,  
and Doug Altman, Head, Medical  
Statistics Laboratory, Imperial  
Cancer Research Fund, London

This concise book:

- Explains what a systematic review is and how to prepare and evaluate one
- Shows the advantages of systematic reviews over traditional reviews
- Includes real-life case studies to illustrate the importance of this new science

**Contents cover:** rationale for systematic reviews; data collection; meta-analysis; checklists for assessing the quality of review articles; updating and correction of reports of reviews; a bibliography of over 250 publications relevant to the science of research synthesis.

Illustrated with tables, graphs, and boxes

118 pages 1995

UK £14.95; Overseas £17.00 (BMA members £13.95; £16.00)

**To order** phone our credit card hotline on  
0171 383 6185/6245 (fax 0171 383 6662)  
or write to: BMJ Publishing Group, PO Box 295,  
London WC1H 9TE.

**BMJ**  
Publishing  
Group

# Every Doctor is a manager

## MANAGEMENT FOR DOCTORS

Jenny Simpson, *Chief Executive, British Association of Medical Managers*  
Richard Smith, *Editor, BMJ*

Every doctor needs to know how to manage, but few receive formal training. This user-friendly guide fills the gap with practical advice on all the aspects of management that doctors need to deal with.

- Written by a team of doctors and business academics
- Uses case studies to show examples of good and bad practice
- Invaluable for both hospital doctors and GPs

Topics covered include: working in teams and leadership; getting the best from people; managing change; making finance work for you

*Buy your copy now and find out what management  
has to offer you*

UK £12.95;  
Overseas £14.00  
(BMA members  
£11.95; £13.00)  
ISBN 0 7279 0558 8  
200 pages  
February 1996

Management  
for

To order phone our credit card  
hotline on 0171 383 6185/6245  
(fax 0171 383 6662) Visa, Mastercard, Amex  
accepted or write to: BMJ Publishing Group,  
PO Box 295, London WC1H 9TE enclosing  
your cheque made payable to BMJ.

Also available from medical  
booksellers, including the BMJ  
Bookshop at BMA House.

**BMJ**  
Publishing  
Group



ing

 **Lamictal** ▽

## PRESCRIBING INFORMATION

**Presentation:** Pale yellow tablets containing 25 mg, 50 mg, 100 mg and 200 mg lamotrigine, and white dispersible/chewable tablets containing 5 mg, 25 mg and 100 mg lamotrigine.

**Uses:** In monotherapy trials, efficacy has been demonstrated in partial epilepsy with or without secondarily generalised tonic-clonic seizures and in primary generalised tonic-clonic seizures.

**Dosage and administration:** *Dosage in monotherapy: Adults and Children over 12 years:* The initial Lamictal dose in monotherapy is 25 mg once a day for two weeks, followed by 50 mg once a day for two weeks. Thereafter, the usual maintenance dose to achieve optimal response is 100-200 mg/day given once a day or as two divided doses. Some patients have required 500 mg/day of Lamictal to achieve the desired response. The recommended initial dose should not be exceeded (see Data Sheet). *Children aged less than 12 years and the Elderly:* Insufficient information available in these patients and consequently not recommended.

*Dosage as add-on therapy: Adults and children over 2 years:* See Data Sheet.

**Contra-indications:** Hypersensitivity to lamotrigine. Significant hepatic impairment.

**Precautions:** Close monitoring of patients who acutely develop any combination of unexplained rash, fever, flu-like symptoms, drowsiness or worsening seizure control is recommended, especially within the first month of starting treatment. Pregnancy and lactation. Renal failure. Avoid abrupt withdrawal.

**Interactions:** Antiepileptic drugs which alter drug metabolising enzymes in the liver (e.g. phenytoin, carbamazepine, phenobarbitone, primidone, sodium valproate) alter the metabolism of Lamictal.

**Side and adverse effects:** During monotherapy trials: headache, tiredness, rash, nausea, dizziness, drowsiness, and insomnia. In use as add-on therapy, severe skin reactions including angioedema, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Rarely hepatic dysfunction, lymphadenopathy, leucopenia and thrombocytopenia have been reported in conjunction with skin rash and all patients who develop rash should be promptly evaluated. (See Data Sheet).

**Legal category:** POM.

**Basic NHS costs:** £14.97 for Starter Pack of 42 x 25 mg tablets (PL3/0272), £99.56 for Calendar Pack of 56 x 200 mg tablets (PL3/0297), £58.57 for pack of 56 x 100 mg tablets (PL3/0274).

**Date of preparation:** March 1995.

BQGT 91-13, 93-18, 94-09.

Lamictal is a Trade mark.

Further information is available on request.

**The Wellcome Foundation Ltd,**

Styal, Manchester M22 5LQ.




**Wellcome**





# THE GROWING NEED FOR A ONCE DAILY INJECTION



Q is for apple

In paediatric infections a once daily dose of ROCEPHIN avoids the distress of repeated and costly injections.

Available as IV or IM ROCEPHIN's proven efficacy and established safety profile<sup>1</sup> is an obvious choice for children, saving both time and money.

#### References

1. Kissling M., Buch W., Fernex M. Medipress (1988) 4(P): 1-7
2. Estimated current cash annual sales worldwide. Data on File. Roche Products Ltd

#### Brief Prescribing Information

**Indications:** Pneumonia, septicaemia, meningitis, bone, skin and soft tissue infections, infections in neutropenic patients, gonorrhoea; peri-operative prophylaxis of infections associated with surgery. Treatment may be started before the results of susceptibility tests are known. **Dosage and Administration:** Rocephin should be administered by deep intramuscular injection, slow intravenous injection, or as a slow intravenous infusion, after reconstitution of the solution. **Adults and children 12 years and over:** Standard dosage - 1g once daily. Severe infections - 2-4g normally once daily. Duration of therapy varies according to course of disease. Gonorrhoea - single dose of 250mg i.m. Peri-operative prophylaxis - usually single dose of 1g; colorectal surgery 2g in conjunction with a suitable agent against anaerobic bacteria. **Children under 12 years:** Standard dosage - 20-50mg/kg once daily. Severe infections - maximum 80mg/kg once daily. Doses of 50mg/kg or over should be given by slow intravenous infusion over at least 30 minutes. **Renal and hepatic**

**impairment:** In the absence of hepatic impairment dose reduction is required only in severe renal failure (creatinic clearance < 10ml/min) when the daily dose should be 2g or less. No dose reduction is required in liver damage provided renal function is intact. In severe renal impairment accompanied by hepatic insufficiency the plasma concentration should be determined at regular intervals and dosage adjusted. Serum concentrations should be monitored in dialysis. **Contra-indications, Warnings etc.** Cephalosporin hypersensitivity. Premature infants. Full-term infants during first six weeks of life. Safety in pregnancy has not been established. **Precautions:** Stated dose should not be exceeded. Caution in patients with a history of hypersensitivity (especially anaphylactic reaction) to penicillins or other non-cephalosporin beta-lactam antibiotics. Anaphylactic shock requires immediate countermeasures. Severe renal impairment accompanied by hepatic insufficiency (see Dosage). **Side-effects and Adverse Reactions:** Gastro-intestinal side-effects including loose stools, diarrhoea, nausea, vomiting, stomatitis and glossitis. Cutaneous reactions including maculopapular rash, pruritus, urticaria, oedema and erythema multiforme. Haematological reactions including anaemia (all grades), leucopenia, neutropenia, thrombocytopenia, eosinophilia, agranulocytosis, positive Coombs' test and prolongation

of prothrombin time. Regular blood counts should be carried out during treatment. Other reactions include headache, dizziness, drug fever and transient elevations in liver function tests. Rarely, glycosuria, oliguria, haematuria, anaphylaxis and bronchospasm. Very rarely, precipitation of ceftriaxone calcium salt in urine in patients on higher than recommended dose. Reversible precipitates of calcium ceftriaxone have been detected by gallbladder sonograms. In symptomatic cases (which are rare), conservative non-surgical management is recommended. Superinfections with yeasts, fungi or other resistant organisms. Rare instances of pseudomembranous colitis. Injection site pain and local phlebitis. **Legal Category:** POM. **Presentations and Basic NHS Cost:** 250mg vials i.m. and i.v. (containing 250mg ceftriaxone) - £2.87. 1g vials i.m. and i.v. (containing 1g ceftriaxone) - £11.46. 2g vials for infusion (containing 2g ceftriaxone) - £22.92. **Product Licence Numbers:** PL 0031 0169 (250mg vials), PL 0031 0171 (1g vials), PL 0031 0172 (2g vials). **Product Licence Holder:** Roche Products Limited, PO Box 8, Welwyn Garden City, Hertfordshire AL7 3AY. Full prescribing information is available on request.

Date of preparation February 1994  
J. 738083

Roche